The samples from TCGA-LUAD were divided into CCL17 high- and low-expression groups based on the CCL17 mRNA-FPKM expression and scored for immunity and stroma, and the immune score was considered a tangible indicator of tumor prognosis. The gene discussed is CCL17; the disease is neoplasm.